Genitope Corporation - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Genitope Corporation Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Genitope Corporation. The Group's principal activities are to research and develop immunotherapies for the treatment of cancer. Immunotherapies are treatments that utilize the immune system to combat diseases. The Group's product, MyVax personalized immunotherapy, is a patient-specific active immunotherapy that is based on the genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. The MyVax is currently in a pivotal Phase 3 clinical trial and additional Phase 2 clinical trials for the treatment of B-cell non-Hodgkin's lymphoma. The Group's Phase III clinical trial is for the treatment of follicular B-cell NHL. The Group is also developing MyVax for the treatment of chronic lymphocytic leukemia (CLL). The Group operates in the domestic market.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report